CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (Reviva or the Company), a late-stage pharmaceutical company developing therapeutics that seek to address unmet medical needs in the areas of the central nervous system (CNS), inflammatory diseases, and cardio-metabolic diseases, today announced that Laxminarayan Bhatt, Ph.D., founder, president and CEO of Reviva, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, taking place virtually October 15-17, 2024.
Maxim Virtual Healthcare Summit 2024
Format: Fireside chat
Date: Tuesday, October 15, 2024
Time: 3:30 PM ET
Location: Default
Registration link: Click here
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapies for diseases that represent unmet medical needs and burdens on society, patients and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiovascular diseases. Reviva’s pipeline currently includes two drug candidates, prilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered within the company. Reviva holds composition patents for Brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Contact the company:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhatt, Ph.D
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
Source: Reviva Pharmaceuticals
Comments are closed, but trackbacks and pingbacks are open.